Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating income during the reporting period...
According to the Zhitong Finance App, Rongchang Biotech (688331.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue of 330 million yuan during the reporting period, an increase of 96.41% over the previous year. Net loss attributable to shareholders of listed companies was 349 million yuan, and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 346 million yuan.